How Does Blood Pressure Affect Treatment Response to SGLT2 Inhibitors in Diabetic Macular Edema?

Summary: In patients with diabetic macular edema (DME) and elevated office systolic blood pressure (OSBP), sodium-glucose cotransporter 2 inhibitors (SGLT2i) significantly reduced treatment burden of intravitreal injections and improved blood pressure and visual acuity compared to standard care without SGLT2i, though it was associated with potential systemic side effects of SGLT2i (not specified).

PICO	Description
Population	Patients with diabetic macular edema (DME) exhibiting elevated office systolic blood pressure (OSBP).
Intervention	Administration of sodium-glucose cotransporter 2 inhibitors (SGLT2i) as a systemic adjunct to standard intravitreal injections (IVRs).
Comparison	Standard care involving intravitreal injections without SGLT2i treatment.
Outcome	SGLT2i use was associated with a reduced number of intravitreal injections, improved blood pressure control, and enhanced visual acuity, suggesting a synergistic effect in managing DME with hypertension. Potential systemic side effects of SGLT2i were not detailed.

Clinical Context

Diabetic macular edema is characterized by vascular endothelial growth factor-driven breakdown of the blood-retinal barrier, leading to fluid accumulation and retinal thickening that threatens central vision. Intravitreal anti-VEGF injections represent the standard of care but require ongoing administration, typically monthly or bimonthly, creating substantial patient burden and healthcare resource utilization. Hypertension commonly coexists with diabetes and independently worsens diabetic retinopathy through increased hydrostatic pressure on damaged capillaries and promotion of vascular permeability. SGLT2 inhibitors have demonstrated blood pressure-lowering effects through natriuresis and volume contraction, alongside anti-inflammatory and metabolic benefits that could theoretically impact retinal health. The confluence of these mechanisms suggests that SGLT2 inhibitors might provide particular benefits for diabetic macular edema patients with coexisting hypertension. This post-hoc subgroup analysis of the COMET trial investigated whether blood pressure status modifies the therapeutic response to SGLT2 inhibitors in diabetic macular edema patients receiving intravitreal therapy.

Clinical Pearls

• SGLT2 inhibitor treatment significantly reduced the number of intravitreal injections required for diabetic macular edema management in patients with elevated systolic blood pressure.
• Visual acuity improved with SGLT2 inhibitor use, indicating that reduced injection frequency did not compromise visual outcomes.
• Blood pressure control improved in the SGLT2 inhibitor group, potentially contributing to both reduced edema burden and cardiovascular risk reduction.
• The beneficial effects appeared specific to patients with elevated blood pressure, suggesting blood pressure modification as a key mechanism underlying the injection-sparing effect.

Practical Application

Ophthalmologists treating diabetic macular edema should communicate with patients’ endocrinologists and primary care providers about the potential benefits of SGLT2 inhibitors, particularly for patients with coexisting hypertension. This finding provides an additional indication favoring SGLT2 inhibitor selection when choosing among diabetes medications for patients requiring intravitreal therapy. For patients already on SGLT2 inhibitors, awareness of potential injection reduction may enhance adherence motivation. Blood pressure optimization should be prioritized as part of comprehensive diabetic eye disease management, and SGLT2 inhibitors may serve dual purposes in this regard. However, the post-hoc nature of this analysis warrants cautious interpretation, and SGLT2 inhibitor prescribing should primarily reflect established cardiovascular and renal indications.

Broader Evidence Context

The COMET trial was designed to evaluate SGLT2 inhibitor effects on diabetic macular edema, and this subgroup analysis extends the findings to specifically characterize the role of blood pressure status. The results align with mechanistic understanding that hypertension exacerbates macular edema through hydrostatic and inflammatory pathways that SGLT2 inhibitors may interrupt. Prior observational studies suggested possible retinal benefits with SGLT2 inhibitors, though randomized evidence has been limited. The findings support the concept that addressing systemic factors alongside local therapy may optimize diabetic eye disease outcomes. This research contributes to the growing evidence base for SGLT2 inhibitor pleiotropic benefits extending beyond glucose control to cardiovascular, renal, and now potentially ocular protection.

Study Limitations

• This represents a post-hoc subgroup analysis, which should be considered hypothesis-generating rather than definitive evidence for clinical decision-making.
• The specific SGLT2 inhibitor used and its dosing were not detailed in the summary.
• Potential systemic side effects of SGLT2 inhibitors were mentioned but not characterized, limiting safety assessment.
• The magnitude of visual acuity improvement and injection reduction were not quantified in the summary.
• Confirmation in prospective studies designed specifically to test this hypothesis is needed before incorporating this finding into routine practice.

Bottom Line

SGLT2 inhibitors reduce intravitreal injection burden and improve visual acuity and blood pressure control in diabetic macular edema patients with elevated systolic blood pressure. Clinicians should consider this potential ocular benefit when selecting diabetes medications for patients requiring intravitreal therapy, particularly those with hypertension. Source: Ishibashi, Ryoichi, et al. “Blood Pressure Status Modulates the Therapeutic Response to Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Macular Edema: A Post Hoc Subgroup Analysis of the COMET Trial.” Read article here.